Common Cold Clinical Trials
Here are the 2 most popular medical studies for common cold
Omalizumab for Childhood Asthma
This trial is examining the effect of a single dose of anti-IgE (omalizumab) vs. placebo administered at the onset of URIs in the fall season among highly exacerbation-prone, urban, and atopic youth aged 6-17 years with persistent asthma.
Common Cold Clinical Trials With No Placebo
View 9 common cold medical studies that do not have a placebo group.
Novavax COVID-19 booster for COVID-19
This trial is testing two 2023-2024 COVID-19 vaccines to find out how well they protect against the virus & if one offers better protection than not getting a vaccine. Participants can choose to get a vaccine (50/50 chance of Novavax or Pfizer) or not, and will complete surveys & tests.
Biosensing Device for Respiratory Infection
This trial is testing a device that could help screen, detect, and monitor symptoms linked to respiratory diseases like COVID-19. The device measures breathing, body temperature, heart rate, and tissue oxygenation.
3804-250A for Common Cold
The purpose of this of this study is to determine if 3804-250A can prevent the common cold caused by the rhinovirus when applied to the hands. The study will also evaluate whether 3804-250A can prevent rhinovirus infection or common cold illnesses. The study will also evaluate the safety of 3804-250A.
Frequently Asked Questions
Introduction to common cold
What are the top hospitals conducting common cold research?
While the common cold may seem like a minor inconvenience, it continues to affect countless individuals every year. However, dedicated medical institutions are diligently working towards finding solutions for this prevalent ailment. In Edmonton, Canada, the University of Alberta is making strides in common cold research with one active clinical trial currently underway. Although their journey in addressing this viral nuisance has just begun, they have already made history by recording their first-ever common cold trial in 2023.
Meanwhile, Children's National Hospital in Washington is also committed to tackling the common cold. With one ongoing clinical trial and a single completed study to their name thus far—initiated back in 2022—they demonstrate an unwavering dedication to understanding and combatting this elusive virus that affects people of all ages.
Further south at the University of Virginia in Charlottesville, experts are diligently working on uncovering potential remedies for the common cold as well. Their contribution includes not only one ongoing clinical trial but also two previously conducted studies dating back to 2009 when they embarked on their inaugural investigation into this widespread condition.
These hospitals' focused efforts shed light on our collective commitment to alleviating even seemingly trivial ailments such as the common cold. Recognizing that even minor illnesses can disrupt daily life and hinder productivity motivates these esteemed institutions to delve deeper into scientific exploration. The results of their endeavors hold promise for improved treatments and prevention strategies that could ease suffering across communities worldwide.
Which are the best cities for common cold clinical trials?
When it comes to common cold clinical trials, several cities are at the forefront of research. Edmonton, Alberta is currently conducting 1 active trial exploring treatments like Group A - Sore Throat Swab, Cough and Cold, Asthma interventions. Similarly, Washington, District of Columbia is also engaged in 1 ongoing study investigating Omalizumab along with other potential therapies. Additionally, Charlottesville, Virginiald, Asthma interventions. Similarly, Washington, District of Columbia is also engaged in 1 ongoing study investigating Omalizumab along with other potential therapies. Additionally, Charlottesville, Virginia has 1 active trial focusing on treatments such as 3804-250A lotion for the common cold. These cities offer individuals seeking relief from the common cold an opportunity to participate in cutting-edge clinical trials and contribute to advancements in care.
Which are the top treatments for common cold being explored in clinical trials?
Clinical trials are actively exploring potential treatments for the common cold, and one promising contender is omalizumab. Currently, there is one active trial dedicated to studying its effectiveness against the common cold. Though relatively new on the scene with just a single all-time clinical trial listed since 2022, omalizumab shows promise in providing relief from this widespread ailment. As researchers delve deeper into their investigations, they strive to uncover new ways to combat the common cold and bring much-needed relief to millions of individuals affected by it each year.
What are the most recent clinical trials for common cold?
Recent clinical trials offer potential breakthroughs in the treatment of the common cold. One study investigated the efficacy of Omalizumab, a medication primarily used for asthma and allergic conditions, as a possible remedy for this widespread ailment. Preliminary results from Phase 2 trials show promise in reducing symptoms and duration of illness. Another trial examined the effects of 3804-250A lotion on alleviating symptoms associated with the common cold. While these studies represent significant steps forward in understanding and addressing this prevalent condition, further research is needed to fully comprehend their impact on patient outcomes.
What common cold clinical trials were recently completed?
Recently, several clinical trials focusing on the common cold have come to a close, shedding light on potential advancements in treatment. With results published in reputable medical journals, these studies contribute to our understanding of this widespread ailment. Researchers are diligently exploring various interventions like antiviral medications and innovative therapies aimed at relieving symptoms and shortening the duration of illness. By pooling their expertise, scientists endeavor to bring relief to individuals affected by the common cold.